07:32 AM EST, 11/14/2025 (MT Newswires) -- Bristol-Myers Squibb Company ( BMY ) in collaboration with Johnson & Johnson ( JNJ ) , said Friday that they have stopped a phase 3 trial of their experimental drug, milvexian, added to the standard of care for patients recovering from a recent acute coronary syndrome event.

The companies said that the decision follows a planned interim analysis by the Independent Data Monitoring Committee, which showed that the study was unlikely to meet its primary effectiveness goal.

No new safety issues were found, and the drug's safety profile matched earlier results, they added.

The companies said the two other phase 3 milvexian trials, one for atrial fibrillation and another for secondary stroke prevention, will continue as planned, with topline data expected in 2026.

Shares of Bristol-Myers Squibb ( BMY ) were down 5% in Friday's premarket activity.